Adrenomedullin 2.0: Adjusting Key Levers for Metabolic Stability

Area of Science:

• Biochemistry
• Pharmacology
• Cardiovascular Science

Background:

• Adrenomedullin (ADM) is a peptide hormone vital for cardiovascular and lymphatic system regulation.
• Low metabolic stability limits ADM's clinical applications, necessitating enhanced plasma half-life for drug development.

Purpose of the Study:

• To analyze the enzymatic degradation of adrenomedullin (ADM) analogues in human blood plasma.
• To develop metabolically stable ADM analogues with prolonged in vitro half-life for therapeutic potential.

Main Methods:

• Solid-phase peptide synthesis (SPPS) was used to create fluorescently labeled ADM analogues.
• Enzymatic degradation and fragmentation patterns in human blood plasma were analyzed.
• Rational design incorporating palmitoylation, lactam-bridging, and Nα-methylation was employed for modification.

Main Results:

• Specific cleavage sites in ADM were identified, guiding the rational design of modified analogues.
• Triple-modified ADM analogues exhibited resistance to enzymatic cleavage in human blood.
• The modified analogues demonstrated an extended in vitro plasma half-life of 5 days compared to wild-type ADM.

Conclusions:

• A triple-modification strategy effectively enhances the metabolic stability and plasma half-life of ADM analogues.
• These modifications did not compromise the selectivity of ADM analogues at the AM1 receptor.
• Developed ADM analogues hold significant promise for future therapeutic applications in cardiovascular and lymphatic diseases.